Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials

A post‐hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of baseline age (<65 and ≥65 years) on the efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes. In PIONEER 9 and 10, patients were randomized to once‐daily oral semaglutide (3, 7 or 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Yuichiro, Yabe, Daisuke, Hertz, Christin Løth, Horio, Hiroshi, Nakamura, Jiro, Nielsen, Anne Møller, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299616/
https://www.ncbi.nlm.nih.gov/pubmed/34622548
http://dx.doi.org/10.1111/dom.14571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299616/
https://www.ncbi.nlm.nih.gov/pubmed/34622548
http://dx.doi.org/10.1111/dom.14571

Ejemplares similares